Study S002317

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT02453711
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 957
Start: 2015-10-01
Primary completion: 2017-03-30
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:semaglutide; DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2014-001540-38; OTHER:U1111-1155-4660; NIH:2014

Registered primary outcomes

Relative Change in Body Weight (%) [Week 0, Week 52]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0028588	Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Kolotkin RL, Clinical obesity	2019	Randomized trial	PMID 30993900 DOI	cites ClinicalTrials.gov:NCT02453711; registry reference BACKGROUND:30993900
R0018235	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. O'Neil PM, Lancet (London, England)	2018	Randomized trial	PMID 30122305 DOI	cites ClinicalTrials.gov:NCT02453711; registry reference RESULT:30122305